Neuro-ophthalmology: Botulinum Toxin, Myasthenia and Idiopathic Intracranial Hypertension

Botulinum toxin: the deadliest poison as a precision drug

To understand the drug you have to understand how a nerve tells a muscle to contract. At every neuromuscular junction, the motor nerve ending stores its messenger — acetylcholine (ACh) — packaged in vesicles. To fire the muscle, those vesicles must dock and fuse with the nerve membrane and spill their ACh into the synapse. That docking is carried out by a set of proteins collectively called SNAREs (including SNAP-25, syntaxin and synaptobrevin), which zip the vesicle to the membrane. Botulinum toxin, produced by Clostridium botulinum, is an enzyme that cleaves these SNARE proteins. With the SNAREs cut, the vesicle can no longer fuse, no ACh is released, and the muscle receives no signal — it is chemically denervated and falls flaccid. This is the same mechanism that, in food-borne botulism, causes the descending paralysis and respiratory failure that make the toxin lethal; the Toxicology chapter covers that poisoning in full. In the clinic we exploit the identical action, but confined to a tiny, deliberately chosen muscle.

What botulinum toxin is used for in the eye

There are four classic ophthalmic uses, and each is simply a matter of picking which muscle to silence. First, blepharospasm and hemifacial spasm: injecting the overactive orbicularis oculi relaxes the involuntary lid closure — the patient in our opening scene. Second, strabismus: injecting an extraocular muscle (classically the medial rectus) weakens it temporarily, letting the eyes realign — a pharmacological alternative to squint surgery in selected cases, especially small or acute deviations. Third, protective ptosis: deliberately paralysing the levator palpebrae superioris so the upper lid drops and closes over a vulnerable eye — used to shield a cornea that cannot protect itself (for example a severe non-healing corneal ulcer or an exposed cornea in facial-nerve palsy), a reversible alternative to stitching the lids together. And beyond neuro-ophthalmology proper, the same toxin softens the glabellar and periocular wrinkles in cosmetic practice — the mechanism is identical, just a different target muscle.

Myasthenia gravis: when the lid droops and the world doubles

If botulinum toxin blocks acetylcholine release, myasthenia is its mirror image — the message is sent but not received. Myasthenia gravis is an autoimmune disease in which antibodies attack and destroy the acetylcholine receptors on the muscle side of the neuromuscular junction. The nerve still releases ACh perfectly well, but there are too few working receptors to hear it — so the muscle fatigues rapidly with use. The eye is the classic first casualty: over half of patients present with ptosis (a drooping eyelid) or diplopia (double vision), because the small, constantly-firing extraocular and levator muscles show fatigue soonest. The signature is variability: the droop worsens through the day and with sustained upgaze, and improves after rest — a fatigable, fluctuating weakness quite unlike the fixed ptosis of a third-nerve palsy or Horner's. Because it arrives disguised as an eye complaint, myasthenia is a diagnosis the ophthalmologist must never miss; it is discussed alongside the neuromuscular-junction pharmacology of the Autonomic / Neuromuscular chapter.

The pharmacology of myasthenia is both diagnostic and therapeutic. The simplest bedside test uses no drug at all: the ice-pack test. Cooling a ptotic lid for two minutes improves the droop, because low temperature slows the enzyme acetylcholinesterase, letting the scarce ACh linger longer at the junction — a positive test points strongly to myasthenia. The historical pharmacological test was the edrophonium (Tensilon) test: edrophonium is a very short-acting acetylcholinesterase inhibitor that transiently raises synaptic ACh; injected intravenously, it produces a dramatic, seconds-to-minutes improvement in the ptosis before wearing off. It is largely retired now (risk of bradycardia, need for resuscitation facilities, and better antibody assays), but it beautifully illustrates the principle. Treatment turns the same lever chronically: pyridostigmine, a longer-acting acetylcholinesterase inhibitor, blocks the breakdown of ACh so that what little the receptors can still hear is amplified — the same class of anticholinesterase drugs you meet in the Autonomic chapter. Pyridostigmine controls symptoms but does not touch the underlying autoimmunity; for that we add immunosuppression — corticosteroids, and steroid-sparing agents such as azathioprine or mycophenolate — and, in appropriate patients, thymectomy.

The drugs that make myasthenia worse

This is the safety flag that saves lives, and a favourite of examiners. Because myasthenia already runs on a razor-thin margin of neuromuscular transmission, any drug that further impairs transmission can tip a stable patient into dangerous weakness — even a myasthenic crisis with respiratory failure. Four groups to commit to memory. Aminoglycoside antibiotics (gentamicin, and by extension the fluoroquinolones such as ciprofloxacin) impair ACh release presynaptically and block the receptor — a prescribing trap that connects to the Antimicrobials chapter. Beta-blockers — including, crucially, topical timolol eye drops used for glaucoma, which are systemically absorbed — can worsen weakness. Magnesium (for instance intravenous magnesium given in obstetrics or for arrhythmia) competitively reduces ACh release and is a classic precipitant. And many others carry warnings — certain calcium-channel blockers, and neuromuscular blocking agents used in anaesthesia, to which myasthenics are exquisitely sensitive. The practical rule: in any patient with myasthenia, check every new drug against this list before you prescribe.

Idiopathic intracranial hypertension: pressure behind the eyes

A young woman with headaches and blurred vision, and two swollen optic discs — the third neuro-ophthalmic pillar. Idiopathic intracranial hypertension (IIH) is raised pressure inside the skull with no tumour or clot to explain it. The pressure is transmitted along the optic nerve sheaths and swells both optic discs — papilloedema — which the ophthalmologist sees directly. The danger is not the headache but the threat to sight: chronic disc swelling can progressively and permanently damage the optic nerves. The classic patient is a young, overweight woman of childbearing age, and it is important to know that certain drugs can cause the picture: the tetracycline antibiotics (doxycycline, minocycline — again a link to the Antimicrobials chapter), high-dose vitamin A and the retinoids (isotretinoin used for acne), and, paradoxically, corticosteroid withdrawal. Weight gain is itself a strong risk factor. So the first move in any IIH work-up is a careful drug history — because sometimes the cure is simply stopping the offending medication.

Once a mass and a venous sinus thrombosis have been excluded (imaging) and the diagnosis confirmed by a high opening pressure on lumbar puncture, treatment aims to lower the pressure and protect the optic nerves. The cornerstones are weight loss and acetazolamide — and here is the elegant link back to glaucoma. Acetazolamide is a carbonic anhydrase inhibitor (CAI). In the eye's ciliary body it reduces aqueous humour production to lower intraocular pressure; in the brain's choroid plexus the same enzyme drives cerebrospinal fluid (CSF) secretion, so the same drug reduces CSF production and lowers intracranial pressure. One molecule, one enzyme, two fluids — a beautiful demonstration of shared mechanism that ties this chapter to the Glaucoma chapter, where acetazolamide and the topical CAIs (dorzolamide, brinzolamide) appear again. Where acetazolamide is not tolerated, topiramate is an alternative that also has weak carbonic-anhydrase activity and the useful side effect of appetite suppression and weight loss. Stopping any causative drug is mandatory, and sight-threatening cases may need surgical CSF diversion or optic-nerve-sheath fenestration.